immatics biotechnologies: Funding, Investors & Team (Sep 2026)
immatics is a biopharmaceutical company that is dedicated to identifying effective targets for cancer immunotherapies by developing specific T cell receptors. The company's pipeline consists of two main product categories: personalized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). These therapies are designed to target challenging solid malignancies and offer unique characteristics that can provide therapeutic benefits to patients at different stages of the disease and with various types of tumors. immatics biotechnologies was founded in Tübingen, Baden-Wurttemberg in the year 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter.
immatics biotechnologies has raised $470M across 5 funding rounds on record, the most recent an undisclosed round of $150M announced in Oct 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
immatics biotechnologies Company Profile and Key Stats
Latest funding round on record: Oct 2024.
immatics biotechnologies Funding Rounds
1 of 5 rounds was announced without a disclosed amount and is excluded from the total.
immatics biotechnologies raised $110M in a Post-IPO Equity announced in Oct 2022.
9 months later, an undisclosed round of $35.0M was announced in Jul 2023.
2 months later, an undisclosed round was announced in Sep 2023 with no disclosed amount.
4 months later, an undisclosed round of $175M was announced in Jan 2024.
9 months later, an undisclosed round of $150M was announced in Oct 2024.
immatics biotechnologies Founders and Leadership Team
Contact details for the immatics biotechnologies team: 1 of 1 has an email address on file.
Start 14-day free trial →immatics biotechnologies Funding Compared to Other Biotechnology Startups
immatics biotechnologies' latest round of $150M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like immatics biotechnologies in Biotechnology and Tübingen
Companies Similar to immatics biotechnologies
Computomics applies AI to bioinformatics data to enable rapid understanding of genomics and drive advanced…
smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug…
Pacifico Biolabs offers fermentation biotechnology for development, production and distribution of…
NanoStruct is a biotechnology company that develops nanostructured sensor chips to identify bacteria and…
Tacalyx, a company originating from Max-Planck-Institute of Colloids and Interfaces in Potsdam, Germany, is…
Primogene is a biotechnology company that provides ingredient development, bioprocess manufacturing, and…
Mbiomics is a company in the field of biotechnology.
At EVANIUM, we make plant compounds like polyphenols and flavonoids more effective by improving their…
Picea Biosolutions is a biotechnology firm. Based on their core platform technology, they develop tailored…
KUPANDO is a pioneering biopharmaceutical firm that is developing TLR 4/7 agonists to boost innate immunity.…
immatics biotechnologies Funding FAQs
What does immatics biotechnologies do?
immatics is a biopharmaceutical company that is dedicated to identifying effective targets for cancer immunotherapies by developing specific T cell receptors. The company's pipeline consists of two main product categories: personalized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). These therapies are designed to target challenging solid malignancies and offer unique characteristics that can provide therapeutic benefits to patients at different stages of the disease and with various types of tumors. immatics biotechnologies was founded in Tübingen, Baden-Wurttemberg in the year 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter.
How much funding has immatics biotechnologies raised?
immatics biotechnologies has raised $470M across 5 rounds on record. The most recent is an undisclosed round of $150M announced in Oct 2024.
When did immatics biotechnologies last raise funding?
immatics biotechnologies' most recent funding round on record is an undisclosed round of $150M, announced in Oct 2024.
Who is the CEO of immatics biotechnologies?
Harpreet Singh is listed as CEO at immatics biotechnologies.
Where is immatics biotechnologies headquartered?
immatics biotechnologies is based in Tübingen, Baden-Wurttemberg, Germany.
How many employees does immatics biotechnologies have?
immatics biotechnologies is in the 251-500 employee band.
How does immatics biotechnologies' funding compare to other Biotechnology startups?
immatics biotechnologies' latest round of $150M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's immatics biotechnologies Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for immatics biotechnologies is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.